Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cimlanod - Bristol-Myers Squibb

Next Previous
X
Search
Drug Profile

Cimlanod - Bristol-Myers Squibb

Alternative Names: BMS-986231; BMS-986231-01; Cimlanod; CXL 1427; HNO Donor; HNO Nitroxyl Donor

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cardioxyl Pharmaceuticals
  • Developer Bristol-Myers Squibb
  • Class Heart failure therapies; Sulfonamides
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Decompensated heart failure; Heart failure

Most Recent Events

  • 28 Jun 2021 No recent reports of development identified for phase-I development in Decompensated-heart-failure(In volunteers) in Hungary (IV, Infusion)
  • 28 Mar 2020 Efficacy data from a phase II trial in Heart failure presented at 2020 Annual Scientific Session of the American College of Cardiology and World Congress of Cardiology (ACC-WCC-2020)
  • 09 Jan 2020 Bristol-Myers Squibb completes a phase II trial for Heart Failure in United Kingdom (NCT03730961)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top